Vorinostat is an oral HDAC inhibitor investigated in the phase II trial setting by Ogura et al. in patients with indolent B cell lymphomas including FL, marginal zone lymphomas (MZL), small lymphocytic lymphoma (SLL), and mucosal associated lymphoma tissue type (MALT) [18]. Here, HDAC9 is linked to marginal zone lymphoma.